^
Association details:
| Biomarker: | ALK negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Single agent pembrolizumab should be considered in eligible patients with PS 0–1, EGFR- and ALK-negative NSCLC and a tumour with a TPS of PD-L1 50% [A¼100% and I, A].
Source:
Title:
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
Excerpt:
...Epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative; 9....
Trial ID:
Source:
Title:
WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Published date:
07/12/2022
Excerpt:
Until Dec. 31st 2021, the median follow-up was 5.6 months. ORR was 57.6% in sintilimab arms vs. 42.9% in pembrolizumab arms, and the confirmed ORR was 45.5% (15/33) vs. 28.6% (10/35), separately.The disease control rate was 87.9% vs. 91.4% in sintilimab and pembrolizumab arms, respectively. The primary endpoint was reached, with 15 confirmed PRs achieved in sintilimab arms. Survival data was still immature. Treatment-related adverse events were comparable between sintilimab and pembrolizumab arms. This head-to-head study of PD-1 inhibitors suggested comparable tumor response and similar safety profile between sintilimab and pembrolizumab.
